Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

Andrew Berens, an analyst from Leerink Partners, assigned the Buy rating on Cullinan Management (CGEM – Research Report). The associated price ...

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...

All subjects have now been enrolled in Island Pharmaceutical’s phase 2b arm of its ISLA-101 trial in dengue fever. ... Read ...

"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...

Dogwood Therapeutics, Inc. announced that it will begin dosing patients in its Phase 2b clinical trial, HALT-CINP, in Q1 2025 to study Halneuron®, a novel Nav 1.7 inhibitor aimed at treating ...

The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Over the past 21 months, the Company has raised $86 million to support the completion of its randomized, multicenter, double-blind, placebo-controlled Phase 2b trial of IGV-001 in patients with ...

All subjects enrolled in Island Pharmaceutical’s phase 2b arm of phase 2a/b PROTECT trial of ISLA-101 in dengue fever Phase 2b study will explore ability of ISLA-101 to reduce symptoms of a ...